两家公司遭证监会立案调查。 2月6日晚间，亚辉龙（688575）、天晟新材（300169）发布公告称，收到中国证监会下发的《立案告知书 》 ，因公司涉嫌信息披露违法违规， 中国证监会决定对公司立案。 证监会对亚辉龙公告涉嫌误导性陈述立案调查 据中国证监会网站消息，2026年1月7日，深圳市亚辉龙生物科技股份有限公司（简称"亚辉龙"）披露签署战略合作框架协议的公告，涉嫌误导性 陈述。近日，证监会已对亚辉龙立案调查。下一步，将在全面调查的基础上依法处理，切实维护市场健康发展。 据悉，1月6日盘后，亚辉龙发布签署战略合作框架协议的公告称，于近日与深圳脑机星链科技有限公司（以下简称"脑机星链"）签署了《战略合 作框架协议》。当天，上交所火速下发问询函，随后，上交所对公司及有关责任人予以监管警示。 责编：万健祎 校对： 刘榕枝 上交所表示，当前"脑机接口"为市场热点概念，为投资者高度关注。特别是，公司股价当日收盘上涨6.52%、成交量较前一个交易日增长299%， 公司披露涉及热点相关信息尤其应当审慎，确保相关信息披露真实、准确、完整，避免对投资者产生误导。公司相关公告对合作方脑机星链技术 路径是否包含侵入式的表述前后不 ...

上交所称，公司上述行为违反了自愿信息披露等相关规则，对亚辉龙及时任董事会秘书王鸣阳予以监管 警示，同时要求公司及董事、高级管理人员采取有效措施对相关违规事项进行整改，结合违规事项，就 公司信息披露及规范运作中存在的合规隐患进行深入排查，制定有针对性的防范措施，切实提高公司信 息披露和规范运作水平。公司需要在收到决定书后的1个月内，向上交所提交经全体董事、高级管理人 员签字确认的整改报告。 2月6日，证监会发布消息，对深圳市亚辉龙生物科技股份有限公司(以下简称"亚辉龙")公告涉嫌误导性 陈述立案调查。 2026年1月7日，亚辉龙披露签署战略合作框架协议的公告，涉嫌误导性陈述。近日，证监会已对亚辉龙 立案调查。下一步，证监会将在全面调查的基础上依法处理，切实维护市场健康发展。 亚辉龙碰瓷"脑机接口" 被上交所监管警示 此前，亚辉龙已经收到上交所监管警示。1月6日收盘后，亚辉龙发布《关于自愿披露签署战略合作框架 协议的公告》公司与深圳脑机星链科技有限公司(以下简称"脑机星链")签订《战略合作框架协议》，双 方将在产品研发、市场推广以及股权投资等方面开展合作，并称脑机星链是一家以人工智能为核心驱动 力，深耕非侵入式与 ...

Core Viewpoint - The article emphasizes the necessity and urgency of transforming China's manufacturing industry from large to strong during the "14th Five-Year Plan" period, focusing on enhancing core capabilities and modernizing the industrial system to support high-quality economic development [1][21]. Group 1: Importance of Transformation - The transformation from large to strong in manufacturing is essential for achieving a stable economic structure, where advanced manufacturing plays a crucial role in national competitiveness and innovation [2][22]. - By 2024, China's per capita GDP is projected to be around $13,000, necessitating a doubling of GDP by 2035 to meet the goal of becoming a moderately developed country [2][22]. - The shift towards high-value, technology-intensive manufacturing is critical for driving industrial upgrades and achieving sustainable economic growth [2][22]. Group 2: Current Progress and Achievements - From 2020 to 2024, China's manufacturing value added increased from 26.6 trillion yuan to 33.6 trillion yuan, highlighting significant growth [8][28]. - The digitalization and green transformation of manufacturing have become new growth engines, with the digital design tool adoption rate rising from 71.5% to 82% during the same period [8][28]. - The structure of the manufacturing industry has been optimized, with high-tech manufacturing value added growing at an annual rate of 8.7% [8][28]. Group 3: Challenges and Constraints - Despite progress, challenges remain, including low R&D investment and insufficient original innovation capabilities among manufacturing enterprises [9][29]. - Key areas such as high-end machinery and core software still face technological bottlenecks that need to be addressed for further advancement [9][29]. - The industry must overcome issues of homogenization and intense competition to enhance productivity and income levels [9][29]. Group 4: Recommendations for Transformation - Building a modern industrial system centered on advanced manufacturing is crucial for supporting high-quality economic circulation [10][31]. - Promoting the integration of traditional, emerging, and future industries is necessary for achieving quality upgrades and fostering new pillar industries [10][31]. - Enhancing the role of enterprises in innovation and establishing collaborative innovation platforms are essential for achieving breakthroughs in core technologies [12][33]. Group 5: Policy and Institutional Support - Strengthening the education and talent integration system is vital for fostering a skilled workforce that can drive manufacturing excellence [19][40]. - Implementing financial support policies for new industrialization and enhancing quality standards will encourage high-quality development in manufacturing [20][41]. - Promoting a culture of quality and innovation within the manufacturing sector is necessary to attract young talent and improve overall industry competitiveness [20][41].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The A-share market is in a state of rotation as the Spring Festival holiday approaches, and it is currently accumulating strength for the Spring rally. It is recommended to allocate technology and consumption sectors evenly and make low-cost layouts [7][14]. - In the bond market, the capital situation remains relatively loose. Falling interest rates and risk aversion continue to drive up the bond market. In the medium to long term, moderately loose monetary policies are expected to strengthen the demand for bond allocation [10][14]. - In the commodity market, short-term fluctuations in precious metals are caused by margin adjustments of domestic and foreign exchanges, but the long-term outlook remains positive [10][14]. 3. Summary by Relevant Catalogs Market行情Analysis Stock Market - The A-share market is in a state of shock adjustment with shrinking trading volume. Overseas market adjustments may have affected market sentiment. The Shanghai Composite Index closed down 0.25%, the Shenzhen Component Index fell 0.33%, and the ChiNext Index dropped 0.73%. The total trading volume was 2.16 trillion yuan, a slight decrease of 1.4% from the previous day [2]. - Cyclical sectors led the gains, while consumer and technology sectors adjusted. Petrochemical and basic chemical industries led the rise, with nearly 20 stocks hitting the daily limit. The consumer sector declined, possibly due to profit-taking after a rapid rise. The technology sector continued to be weak, affected by the decline of US technology stocks [5]. - The market style is rotating, and the Spring rally is still expected. The market is currently in a state of rotation, and it is difficult to have a dominant sector in the short term. Sectors such as photovoltaics, commercial aerospace, and non-ferrous metals may have new catalysts in the future, and consumer and real estate-related sectors may also present investment opportunities. It is recommended to allocate assets evenly and make low-cost layouts [7]. Bond Market - The treasury bond futures market rose across the board, with long-term contracts leading the gains. The 30-year main contract (TL2603) rose 0.42%, the 10-year main contract (T2603) rose 0.08%, the 5-year contract (TF2603) rose 0.03%, and the 2-year contract (TS2603) rose 0.02% [10]. - The central bank net withdrew 146 billion yuan, but the 14-day reverse repurchase continued to support cross - festival liquidity. Falling Shibor rates and risk aversion are driving the bond market up, and moderately loose monetary policies are expected to strengthen the demand for bond allocation in the medium to long term [10]. Commodity Market - The commodity index declined, and precious metals fluctuated significantly again. The Nanhua Commodity Index closed down 0.86%. Shanghai silver led the decline with a 14.92% drop, while LPG and alumina rose slightly [10]. - The increase in overseas margins led to significant fluctuations in precious metals. The Chicago Mercantile Exchange Group raised the initial margins for gold and silver futures. Precious metals may continue to fluctuate in the short term but are expected to rise in the long term [10]. - The price of alumina rose, but there is still long - term overcapacity pressure. The rise in alumina futures is due to a local spot shortage and pre - holiday inventory replenishment expectations, but it is constrained by long - term overcapacity [10]. Trading Hotspot Tracking Recent Popular Varieties | Variety | Core Logic | Follow - up Concerns | | --- | --- | --- | | AI Application | Acceleration of product applications represented by Alibaba Qianwen and Google GEMINI | 1. Transformation of application scenarios; 2. Product technology upgrade and breakthrough [12] | | Commercial Aerospace | Establishment of commercial aerospace companies and strong support for development | 1. Domestic reusable rocket launch situation; 2. Technological breakthroughs of overseas leaders such as SPACEX [12] | | Nuclear Fusion | Acceleration of industrialization in the mid - upstream | 1. Project progress; 2. Industry bidding situation [12] | | Quantum Technology | Technological breakthroughs and strategic emerging industries | 1. Domestic policy support; 2. Progress of key domestic and foreign projects [12] | | Brain - Computer Interface | 14th Five - Year Plan policy support and overseas technological progress | 1. Domestic technological progress; 2. Progress of foreign company projects [12] | | Robotics | Continuous product upgrading and accelerating industrialization | 1. Tesla's order release rhythm; 2. Technological progress of domestic enterprises [12] | | Big Consumption | Policy support for consumption upgrade | 1. Economic recovery; 2. Further stimulus policies [12] | | Brokerage | A - share trading volume remains above 2 trillion, and deposit transfer | 1. A - share market trading volume; 2. Possible changes in trading systems [12] | | Precious Metals | Continuous central bank purchases and expected Fed rate cuts | 1. Further Fed rate cut expectations; 2. Geopolitical risks [12] | | Non - Ferrous Metals | Weak US dollar index and supply constraints | 1. Changes in the US dollar index; 2. Global regional supply changes [12] | Recent Core Ideas - In the equity market, the current market is in a rotation state, and it is recommended to allocate technology and consumption sectors evenly and make low - cost layouts [14]. - In the bond market, the capital situation is loose, and the bond market is expected to continue to rise. In the medium to long term, the demand for bond allocation will be strengthened [14]. - In the commodity market, short - term fluctuations in precious metals are expected, but the long - term outlook is positive [14].

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a significant rebound, particularly in innovative drugs, with several companies reporting strong earnings forecasts and positive growth trends [1][8]. Group 1: Innovative Drug Sector - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a rise of nearly 2% after opening lower, indicating strong investor interest [1][8]. - Innovent Biologics (诺诚健华) led the gains with a rise of over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1][8]. - Other companies like Rongchang Biopharmaceutical and CanSino Biologics also reported profitability, with net profit growth exceeding 100% year-on-year [1][8]. Group 2: Medical Sector - The medical sector is also showing positive momentum, with AI healthcare and CXO-related stocks active; Ark Health (方舟健客) led with a 4.71% increase [3][10]. - Ark Health forecasts a profit of 7 to 10 million yuan for 2025, indicating a turnaround from previous losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3][10]. - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to be profitable, with several companies anticipating net profit growth of over 100% [3][10]. Group 3: Market Trends and Investment Opportunities - Despite the positive earnings outlook, the recent performance of the pharmaceutical sector has diverged from these fundamentals, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing four consecutive weeks of declines [5][12]. - The current market conditions may present a favorable opportunity for accumulation in the Hong Kong pharmaceutical sector, particularly through ETFs, which offer higher efficiency and flexibility [5][12]. - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds for a comprehensive exposure to innovative drug companies, with the top ten holdings accounting for over 73% of the portfolio [6][12].

Group 1 - The core viewpoint of the article highlights the recent performance of the Kexin Innovation Drug ETF (589720), which has seen a net inflow of over 1 billion yuan in the past 20 days, indicating a focus on theme-based investment opportunities in the pharmaceutical sector [1] - The pharmaceutical sector currently lacks a clear investment theme, with innovative drugs undergoing a phase of profit realization and adjustment, suggesting that future opportunities will revolve around thematic investments such as brain-computer interfaces, AI healthcare, and small nucleic acids [1] - The raw material drug sector is emphasized as being at a bottoming phase, with potential for mid-term cyclical improvement driven by rising prices in chemicals and the introduction of new businesses like small nucleic acids, peptides, and ADCs [1] Group 2 - The Kexin Innovation Drug ETF (589720) tracks the Kexin Innovation Drug Index (950161), which focuses on the research, development, and production of innovative drugs, with a daily price fluctuation limit of 20% [1] - The index emphasizes high growth and innovation within the biopharmaceutical industry, reflecting the performance and market value of companies engaged in new drug development [1] - The raw material and intermediate drug industry has experienced a 4-5 year price decline, but with the recent rise in commodity and upstream chemical prices, there is an expectation for price improvement and stabilization in the market [1]

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Add" for 药明康德 (WuXi AppTec) [6][53]. Core Insights - The report highlights the recent approval of new drugs, including 埃诺格鲁肽注射液 (Energulutide Injection), which is the first of its kind approved for adult type 2 diabetes patients [16]. - The report emphasizes the importance of the recent policies from the National Medical Security Administration aimed at enhancing the medical insurance landscape, which is expected to improve service levels and create development opportunities in the industry [14]. - The report notes significant growth in product revenues for companies like 信达生物 (Innovent Biologics) and 康方生物 (CanSino Biologics), indicating a positive trend in the sector [31][32]. Industry News - The National Medical Security Administration issued a notice to accelerate the cultivation and application of new scenarios in the medical insurance field, which is expected to enhance service levels and create industry development opportunities [14]. - The Ministry of Industry and Information Technology, along with seven other departments, released a plan for the high-quality development of the traditional Chinese medicine industry from 2026 to 2030, aiming to strengthen the entire industry chain [15]. - The report mentions that in 2025, the employee medical insurance personal account had a total of 4.64 billion person-times, with a total amount of 68.77 billion yuan [15]. Company Announcements - 信达生物 (Innovent Biologics) reported a strong revenue growth of approximately 45% year-on-year for 2025, with a significant increase in Q4 revenue due to new drugs being included in the national medical insurance directory [31]. - 康方生物 (CanSino Biologics) granted exclusive commercialization rights for 伊喜宁® (Evinacumab) to 济川药业 (Jichuan Pharmaceutical), receiving an upfront payment of 80 million yuan [32]. - 恒瑞医药 (Hengrui Medicine) has had several drug applications accepted by the FDA and NMPA, indicating ongoing progress in its product pipeline [33]. Market Review - The report notes a decline in major indices, with the SW Pharmaceutical and Biological sector down by 0.97% during the week of January 30 to February 5, 2026 [45]. - The overall industry P/E ratio as of February 5, 2026, was reported at 51.01 times, with a valuation premium of 261% relative to the CSI 300 index [47]. Weekly Strategy - The report suggests focusing on investment opportunities in innovative drugs, CXO, and upstream life sciences, while also monitoring companies involved in small nucleic acids and AI applications [53].

Group 1 - The concept of "future industries" has gained significant attention in 2026, with a focus on development and strategic planning at various governmental levels [1][3] - Future industries are defined as emerging sectors driven by cutting-edge technologies, currently in the early stages of development, characterized by strategic significance and potential for disruption [2][3] - The "14th Five-Year Plan" emphasizes the importance of forward-looking layouts for future industries, aiming to explore diverse technological routes and typical application scenarios [2][3] Group 2 - China's future industry development is transitioning from technology catch-up to proactive layout, with a mix of leading, parallel, and following positions across different sectors [4][5] - Key regions like Beijing, Guangdong, and Jiangsu are making strides in future industries, with specific focuses on quantum technology, biomanufacturing, and 6G communications [12][14] - Shanghai and Anhui are highlighted as leaders in future industry development, with Shanghai leveraging its comprehensive advantages and Anhui focusing on quantum technology and fusion energy [5][8] Group 3 - Shanghai's strategic initiatives include a dynamic cultivation system for future industries, supported by a fund of approximately 15 billion yuan, aimed at reducing costs and accelerating product commercialization [7][10] - Anhui has established a robust ecosystem for quantum technology and fusion energy, with a significant concentration of enterprises and research institutions [9][11] - The development of future industries is not limited to coastal regions, as demonstrated by Anhui's success in quantum technology and its plans for commercializing fusion energy [8][10] Group 4 - Local governments are encouraged to create open and inclusive innovation ecosystems to support the growth of future industries, emphasizing the importance of regional characteristics and market orientation [17][18] - The national government is implementing major strategic projects and increasing investment in future industries to foster a competitive environment across regions [15][16] - Future industries are expected to thrive through proactive planning, localized development strategies, and supportive policy measures [18]

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [28][37]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.91% from January 23 to February 5, 2026, which is approximately 0.74 percentage points lower than the index [12]. - Most sub-sectors within the industry recorded negative returns during the same period, with offline pharmacies and vaccine sectors showing the best performance, increasing by 3.01% and 0.12% respectively, while other sectors like biological products and chemical preparations saw declines of 3.28% and 3.27% [13]. - Approximately 34% of stocks in the industry recorded positive returns, while 66% experienced negative returns during the reporting period [14]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 51.00 times as of February 5, 2026, indicating a decrease in industry valuation [18]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.91% from January 23 to February 5, 2026 [12]. - Most sub-sectors recorded negative returns, with offline pharmacies and vaccines performing relatively well [13]. - About 34% of stocks in the industry had positive returns, with significant variations in individual stock performance [14]. - The industry valuation has decreased, with a PE ratio of approximately 51.00 times [18]. 2. Industry News - The 11th batch of national procurement results is set to be implemented in February, with notifications already released by 17 provinces [26]. - The National Medical Insurance Administration has issued a notice to accelerate the cultivation and opening of application scenarios in the medical insurance field [25]. 3. Company Announcements - Jianyou Co., Ltd. announced that its subsidiary received FDA approval for its product, sodium selenite injection [27]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector as part of the 14th Five-Year Plan, with ongoing policy support [28]. - Recommended sectors for investment include medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, hospital and diagnostic services, traditional Chinese medicine, innovative drugs, biological products, and CXO services [29].

文章来源：神经未来 转载要求：可以直接转载，请在文首注明来源 2026年2月5日，证监会IPO辅导公示系统显示， 博睿康 已向上海证监局提交IPO辅导备案，正式启动上市进程 。 作为国内脑机接口（BCI）领域最早一批系统级企业之一，博睿康的核心产品为 微创植入式脑机接口系统 NEO 。据公开信息， NEO 已于 2025 年完成注册性临床试验，并进入国家药监局创新医疗器械特别审查程序， 有望成为 国内首个实现商业化落地 的植入式脑机接口产品 。 在海外脑机接口持续取得阶段性突破、国内政策与临床同步加速的背景下，博睿康的 IPO 动向，被视为中国医疗级 BCI 从"科 研主导"迈向"产业化验证"的重要信号。 # 海内外脑机接口进展提速，产业关注度持续升温 近一个月内，脑机接口赛道连续释放多重信号： 海外公司在侵入式技术路径上的持续突破，与国内企业在监管、临床和政策端的同步推进，使脑机接口从"前沿探索"逐步进入 可被资本 和产业评估的阶段 。 # 医疗仍是 BCI 最大基本盘，市场规模正在被重新评估 从全球视角看， 医疗健康是脑机接口当前最成熟、占比最高的应用方向 。 综合多家研究机构测算，医疗领域通常占整体 B ...